Vycor Develops New Device Targeted at the Pediatric Market Medical, Healthcare
By a News Reporter-Staff News Editor at Health & Medicine Week -- Vycor Medical, Inc. ("Vycor") (OTCBB: VYCO) announced that it has finalized the design prototypes of two new product variations of its existing VBAS product suite to be developed specifically for endoscopic work within the ventricles of the brain. Initially this device will be targeted at the pediatric market. The product was developed in close collaboration with a leading pediatric neurosurgeon. It is anticipated that the new products will be available commercially by the end of the year.
VBAS is a suite of clear cylindrical disposable devices which provide neurosurgeons a stable, minimally invasive working channel to access targeted sites within the brain, such as tumors. The "blade retractor" has been the standard of care device for brain access and retraction for more than 50 years. VBAS is now approved in over 100 hospitals in the U.S. and the number continues to grow. To date, more than 4,000 surgeries have been performed utilizing VBAS.
As part of Vycor's strategy to drive growth, New Product Development is targeted at both driving the use of its existing VBAS product range through ancillaries that will facilitate its use and through new product extensions to broaden VBAS applicability to procedures currently not addressed by its existing product line. Management has estimated, based on AANS statistics by cranial procedure, that there are in the U.S. alone approximately 200,000 annual applicable procedures for its current VBAS device range and an additional 130,000 procedures that could be addressed through product extensions.
The two new devices will help address an estimated 25,000 new procedures annually.
"We believe that the addition of these two new products into the market represents an exciting opportunity for the Company to address under-served pediatric neurosurgical needs in the market and is consistent with our stated objective of adding new product variations to our core VBAS product line," stated David Cantor, Vycor's President (see also Medical, Healthcare).
Keywords for this news article include: Medical, Healthcare, Pediatrics.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC